{
    "nctId": "NCT02891681",
    "briefTitle": "Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment",
    "officialTitle": "Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Breast Tumors, Cancer of Breast, Cancer of the Breast, Malignant Neoplasm of Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 41,
    "primaryOutcomeMeasure": "Pathologic Response Based on Miller-Payne Grading System",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Scheduled to receive neoadjuvant chemotherapy for the treatment of newly diagnosed, locally advanced breast cancer or scheduled to receive neoadjuvant endocrine therapy with the eventual goal of surgery of newly diagnosed clinical stage II-III ER+ HER2- breast cancer (for the endocrine therapy cohort)\n* At least 18 years of age\n* Female\n* Able to understand and willing to sign an IRB-approved written informed consent document\n\nExclusion Criteria:\n\n* Pregnant and/or breastfeeding\n* Prior history of breast cancer\n* Prior history of chest wall radiation\n* Prior history of breast reconstruction, reduction, or augmentation",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}